Current Urology Reports

, Volume 8, Issue 3, pp 185–189 | Cite as

Testosterone replacement therapy and prostate cancer: A word of caution

  • Timothy C. Brand
  • Edith Canby-Hagino
  • Ian M. Thompson


The number of men for whom testosterone is prescribed is rapidly increasing. The aging man normally demonstrates a gradual decline in testosterone. Symptoms of hypogonadism include erectile dysfunction, diminished libido, sarcopenia, increased adiposity, osteopenia and osteoporosis, impaired cognition, and depression. There is a paucity of data regarding both efficacy and safety of testosterone replacement therapy. Testosterone levels have been shown to modulate prostate cancer risk and progression. A prospective evaluation of prostate cancer risk with testosterone replacement therapy has not been conducted. We outline concerns and recommendations for the use of testosterone replacement therapy in the aging man.


Prostate Cancer Testosterone Digital Rectal Examination Free Testosterone Prostatic Intraepithelial Neoplasia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gore J, Raifer J: Testosterone and the aging male: where do we stand? Am J Urol Rev 2005, 3:440–442.Google Scholar
  2. 2.
    Isidori AM, Greco EA, Aversa A: Androgen deficiency and hormone-replacement therapy. BJU Int 2005, 96:212–216.PubMedCrossRefGoogle Scholar
  3. 3.
    Haren MT, Morley JE, Chapman IM, et al.: Defining ‘relative’ androgen deficiency in aging men: how should testosterone be measured and what are the relationships between androgen levels and physical, sexual and emotional health? Climacteric 2002, 5:15–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Katz A: Androgen replacement therapy in aging men. Nurse Pract 2004, 29:58–64.PubMedCrossRefGoogle Scholar
  5. 5.
    Blazer D: Testosterone and Aging: Clinical Research Directions. Washington, DC: National Academies Press; 2003.Google Scholar
  6. 6.
    Testosterone use in the United States [press release]. Fairfield, CT: Intercontinental Marketing Services (IMS) Health; 2003.Google Scholar
  7. 7.
    Tenover JS: Declining testicular function in aging men. Int J Impot Res 2003, 15(Suppl 4):S3–S8.PubMedCrossRefGoogle Scholar
  8. 8.
    Mohr BA, Guay AT, O’Donnell AB, et al.: Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol (Oxf) 2005, 62:64–73.CrossRefGoogle Scholar
  9. 9.
    Report of National Institute on Aging Advisory Panel on Testosterone Replacement in Men. J Clin Endocrinol Metab 2001, 86:4611–4614.Google Scholar
  10. 10.
    Diver MJ, Imtiaz KE, Ahmad AM, et al.: Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol 2003, 58:710–717.CrossRefGoogle Scholar
  11. 11.
    Broderick GA, Lue TF: Evaluation and nonsurgical management of erectile dysfunction and priapism. In Campbell’s Urology, edn 8. Edited by Walsh PC. Philadelphia: Elsevier; 2002:1619–1671.Google Scholar
  12. 12.
    Halland A, Jonler M, Pedersen KV: Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency. Scand J Urol Nephrol 2005, 39:87–88.PubMedCrossRefGoogle Scholar
  13. 13.
    Rossouw JE, Anderson GL, Prentice RL, et al.: Risks and benefits of estrogen plus progrestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial [see comment]. JAMA 2002, 288:321–333.PubMedCrossRefGoogle Scholar
  14. 14.
    Villareal DT, Morley JE: Trophic factors in aging: should older people receive hormonal replacement therapy? Drugs Aging 1994, 4:492–509.PubMedGoogle Scholar
  15. 15.
    Harman SM, Metter EJ, Tobin JD, et al.: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86:724–731.PubMedCrossRefGoogle Scholar
  16. 16.
    Kelleher S, Conway AJ, Handelsman DJ: Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004, 89:3813–3817.PubMedCrossRefGoogle Scholar
  17. 17.
    Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Thompson IM, Pauler DK, Goodman PJ, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter [see comment]. N Engl J Med 2004, 350:2239–2246. [Published erratum appears in N Engl J Med 2004, 351:1470.]PubMedCrossRefGoogle Scholar
  19. 19.
    Thompson IM, Ankerst DP, Chi C, et al.: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005, 294:66–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Morgentaler A, Bruning CO 3rd, DeWolf WC: Occult prostate cancer in men with low serum testosterone levels. JAMA 1996, 276:1904–1906.PubMedCrossRefGoogle Scholar
  21. 21.
    Kim J, Coetzee GA: Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem 2004, 93:233–241.PubMedCrossRefGoogle Scholar
  22. 22.
    Gormley GJ: Role of 5 alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol Clin North Am 1991, 18:93–98.PubMedGoogle Scholar
  23. 23.
    Wilson JD, Roehrborn C: Long-term consequences of castration in men: lessons from the Skoptzy and the eunuchs of the Chinese and Ottoman courts [see comment]. J Clin Endocrinol Metab 1999, 84:4324–4331.PubMedCrossRefGoogle Scholar
  24. 24.
    Jenkins JS: Long-term consequences of castration in men [comment]. J Clin Endocrinol Metab 2001, 86:1844.PubMedCrossRefGoogle Scholar
  25. 25.
    Wu JP, Gu FL: The prostate 41–65 years post castration: an analysis of 26 eunuchs. Chin Med J 1987, 100:271–272.PubMedGoogle Scholar
  26. 26.
    Wu CP, Gu FL: The prostate in eunuchs. Prog Clin Biol Res 1991, 370:249–255.PubMedGoogle Scholar
  27. 27.
    Thompson IM, Goodman PJ, Tangen CM, et al.: The influence of finasteride on the development of prostate cancer [see comment]. N Engl J Med 2003, 349:215–224.PubMedCrossRefGoogle Scholar
  28. 28.
    Gann PH, Hennekens CH, Ma J, et al.: Prospective study of sex hormone levels and risk of prostate cancer [see comment]. J Natl Cancer Inst 1996, 88:1118–1126.PubMedCrossRefGoogle Scholar
  29. 29.
    Shaneyfelt T, Husein R, Bubley G, et al.: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000, 18:847–853.PubMedGoogle Scholar
  30. 30.
    Huggins C, Hodges C: Studies on prostateic cancer 1: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293.Google Scholar
  31. 31.
    Thompson IM, Zeidman EJ, Rodriguez FR: Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate [see comment]. J Urol 1990, 144:1479–1480.PubMedGoogle Scholar
  32. 32.
    Gerstenbluth RE, Maniam PN, Corty EW, et al.: Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002, 23:922–926.PubMedGoogle Scholar
  33. 33.
    Kuhnert B, Byrne M, Simoni M, et al.: Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol 2005, 153:317–326.PubMedCrossRefGoogle Scholar
  34. 34.
    Swerdloff RS, Wang C: Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003, 6:207–211.PubMedCrossRefGoogle Scholar
  35. 35.
    von Eckardstein S, Nieschlag E: Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 2002, 23:419–425.Google Scholar
  36. 36.
    Guay AT, Perez JB, Fitaihi WA, et al.: Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer [see comment]. Endocr Pract 2000, 6:132–138.PubMedGoogle Scholar
  37. 37.
    Curran MJ, Bihrle W 3rd: Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999, 53:423–424.PubMedCrossRefGoogle Scholar
  38. 38.
    Arnold JT, Le H, McFann K, et al.: Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 2005, 288:E573–E584.PubMedCrossRefGoogle Scholar
  39. 39.
    Schlesinger C, Bostwick DG, Iczkowski KA: High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol 2005, 29:1201–1207.PubMedCrossRefGoogle Scholar
  40. 40.
    De Marzo AM, Meeker AK, Zha S, et al.: Human prostate cancer precursors and pathobiology. Urology 2003, 62:55–62.PubMedGoogle Scholar
  41. 41.
    Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348–2351.PubMedCrossRefGoogle Scholar
  42. 42.
    Gaylis F, Lin D, Ignatoff J, et al.: Prostate cancer in men using testosterone supplementation. J Urol 2005, 174:534–538; discussion 538.PubMedCrossRefGoogle Scholar
  43. 43.
    Loughlin KR: Testosterone replacement therapy: a rush to judgment? [comment]. J Urol 2004, 172:827–828.PubMedCrossRefGoogle Scholar
  44. 44.
    Jackson JA, Waxman J, Spiekerman AM: Prostatic complications of testosterone replacement therapy. Arch Intern Med 1989, 149:2365–2366.PubMedCrossRefGoogle Scholar
  45. 45.
    Ebling DW, Ruffer J, Whittington R, et al.: Development of prostate cancer after pituitary dysfunction: a report of 8 patients. Urology 1997, 49:564–568.PubMedCrossRefGoogle Scholar
  46. 46.
    Swerdlow AJ, Schoemaker MJ, Higgins CD, et al.: Cancer incidence and mortality in men with Klinefelter syndrome: a cohort study. J Natl Cancer Inst 2005, 97:1204–1210.PubMedCrossRefGoogle Scholar
  47. 47.
    Hwang JJ, Dharmawardana PG, Uchio EM, et al.: Prostate cancer in Klinefelter syndrome during hormonal replacement therapy. Urology 2003, 62:941.PubMedCrossRefGoogle Scholar
  48. 48.
    Pienkos EJ, Meisner LF: Adenocarcinoma of the prostate in a 41-year-old man with XXY karyotype and chronic lymphocytic leukemia: report of a case. J Urol 1991, 145:148–150.PubMedGoogle Scholar
  49. 49.
    Morales A: Testosterone treatment for the aging man: the controversy. Curr Urol Rep 2004, 5:472–477.PubMedCrossRefGoogle Scholar
  50. 50.
    Agarwal PK, Oefelein MG: Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005, 173:533–536.PubMedCrossRefGoogle Scholar
  51. 51.
    Kaufman JM, Graydon RJ: Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men [see comment]. J Urol 2004, 172:920–922.PubMedCrossRefGoogle Scholar
  52. 52.
    Liverman CT, Blazer DG: Testosterone and Aging: Clinical Research Directions. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Washington, DC: National Academies Press; 2004.Google Scholar
  53. 53.
    Gooren LJ, Bunck MC: Transdermal testosterone delivery: testosterone patch and gel. World J Urol 2003, 21:316–319.PubMedCrossRefGoogle Scholar
  54. 54.
    Jockenhovel F: Testosterone supplementation: what and how to give. Aging Male 2003, 6:200–206.PubMedCrossRefGoogle Scholar
  55. 55.
    Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring [see comment]. N Engl J Med 2004, 350:482–492.PubMedCrossRefGoogle Scholar
  56. 56.
    Schultheiss D, Machtens S, Jonas U: Testosterone therapy in the ageing male: what about the prostate? Andrologia 2004, 36:355–365.PubMedCrossRefGoogle Scholar
  57. 57.
    Morales A: Androgen replacement therapy and prostate safety. Eur Urol 2002, 41:113–120.PubMedCrossRefGoogle Scholar
  58. 58.
    Tenover JL: Male hormone replacement therapy including “andropause”. Endocrinol Metab Clin North Am 1998, 27:969–987.PubMedCrossRefGoogle Scholar
  59. 59.
    Alexandersen P, Christiansen C: The aging male: testosterone deficiency and testosterone replacement: an up-date. Atherosclerosis 2004, 173:157–169.PubMedCrossRefGoogle Scholar
  60. 60.
    Tan RS, Culberson JW: An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas 2003, 45:15–27.PubMedCrossRefGoogle Scholar
  61. 61.
    Snyder PJ: Hypogonadism in elderly men: what to do until the evidence comes [see comment]. N Engl J Med 2004, 350:440–442.PubMedCrossRefGoogle Scholar
  62. 62.
    Schaeffer EM, Walsh PC: Risks of testosterone replacement [comment]. N Engl J Med 2004, 350:2004–2006.PubMedCrossRefGoogle Scholar
  63. 63.
    Slater S, Oliver RT: Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000, 17:431–439.PubMedCrossRefGoogle Scholar
  64. 64.
    Lund BC, Bever-Stille KA, Perry PJ: Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy 1999, 19:951–956.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Timothy C. Brand
    • 1
  • Edith Canby-Hagino
  • Ian M. Thompson
  1. 1.Department of UrologyUniversity of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations